- Additional Authors
- Subject
- Genre/Form
- Technical reports.
- Note
- "Evidence-based synthesis program."
- "October 2012."
- Bibliography (note)
- Includes bibliographical references (pages 54-70).
- Funding (note)
- Prepared for: Department of Veterans Affairs, Veterans Health Administration, Quality Enhancement Research Initiative, Health Services Research & Development Service, Washington, DC 20420. Prepared by: Evidence-based Synthesis Program (ESP) Center, West Los Angeles VA Medical Center, Los Angeles, CA, Paul G. Shekelle, M.D., Ph. D., Director.
- VA-ESP
- Source of Description (note)
- Description based on online resource; title from PDF cover (VA, viewed April 22, 2021).
- Call Number
- GPO Internet VA 1.107/3:L 97
- OCLC
- 858650008
- Author
Shekelle, Paul G., author.
- Title
Treatment of metastatic non-small cell lung cancer : a systematic review of comparative effectiveness and cost-effectiveness / prepared for, Department of Veterans Affairs, Veterans Health Administration, Quality Enhancement Research Initiative, Health Services Research & Development Service ; prepared by, Evidence-based Synthesis Program (ESP) Center, West Los Angeles VA Medical Center ; principal investigators, Paul G. Shekelle, Alicia R. Maher ; research associates, Isomi M. Miake-Lye, Jessica M. Beroes.
- Publisher
Washington, DC : Department of Veterans Affairs, Veterans Health Administration, Quality Enhancement Research Initiative, Health Services Reseach & Development Service, 2012.
- Description
1 online resource (iv, 82 pages) : one illustration
- Type of Content
text
- Type of Medium
computer
- Type of Carrier
online resource
- Bibliography
Includes bibliographical references (pages 54-70).
- Summary
Lung cancer is the leading cause of cancer death in both men and women in the United States, and male Veterans seeking care at VA hospitals have a much higher age-specific incidence of lung cancer than males in the general population. The personal and economic significance of lung cancer has led to a vast research endeavor to try and identify new and more effective treatments. Most patients with lung cancer are diagnosed when the cancer is already advanced (stage IIIB or IV), and they are no longer candidates for surgical resection. Small cell lung cancer and non-small cell lung cancer (NSCLC) are different diseases in terms of treatment. Until recently, all therapies for advanced NSCLC were based on their cytotoxic properties. In the last few years, several novel agents aimed at specific molecular targets have been developed. This review was requested to evaluate the current evidence on the effectiveness and cost-effectiveness of treatments for advanced lung cancer.
- Funding
Prepared for: Department of Veterans Affairs, Veterans Health Administration, Quality Enhancement Research Initiative, Health Services Research & Development Service, Washington, DC 20420. Prepared by: Evidence-based Synthesis Program (ESP) Center, West Los Angeles VA Medical Center, Los Angeles, CA, Paul G. Shekelle, M.D., Ph. D., Director.
VA-ESP 05-226
- Connect to:
- Added Author
Ruelaz Maher, Alicia, author.
United States. Department of Veterans Affairs. Health Services Research and Development Service, issuing body.
West Los Angeles VA Medical Center. Evidence-Based Synthesis Program Center.
Quality Enhancement Research Initiative (U.S.)
Evidence-based Synthesis Program (U.S.)
- Gpo Item No.
0985-A-12 (online)
- Sudoc No.
VA 1.107/3:L 97
- Research Call Number
GPO Internet VA 1.107/3:L 97